Drugs / HIV p17/p24:Ty-VLP
last change Mar 1996 re-read 2 minutes ago

HIV p17/p24:Ty-VLP

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00001053 ? → Mar 1996 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HIV p17/p24:Ty-VLP ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001053
Modality Vaccine “HIV p17/p24:Ty-VLP (virus-like particles) vaccineNCT00001053
Route Intramuscular “Volunteers receive HIV p17/p24:Ty-VLP vaccine or placebo by IM injection” NCT00001053